Filing Details

Accession Number:
0001567619-20-010595
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-15 17:03:08
Reporting Period:
2020-05-13
Accepted Time:
2020-05-15 17:03:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1254748 M Rebecca Henderson One Idexx Drive
Westbrook ME 04092
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-13 5,974 $64.69 20,670 No 4 M Direct
Common Stock Disposition 2020-05-13 5,974 $286.66 14,696 No 4 S Direct
Common Stock Acquisiton 2020-05-13 7,422 $63.95 22,118 No 4 M Direct
Common Stock Disposition 2020-05-13 7,422 $286.66 14,696 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2020-05-13 5,974 $0.00 5,974 $64.69
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2020-05-13 7,422 $0.00 7,422 $63.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-05-06 No 4 M Direct
300 2025-05-05 No 4 M Direct
Footnotes
  1. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  2. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  3. Not spplicable.